COVID-19 primary antivirals Kaletra·Chloroquine recommended

Central clinical TF "Ribavirin·Interferon, side effects are severe and not recommended as primary drugs"

Result of the fifth meeting, "Self-healing is possible but active consideration for old and serious patients"

The central clinical TF will recommend antiretroviral agents Kaletra, antimalarial agents Chloroquine, and Hydroxychloroquine as the primary antiviral drugs for COVID-19.

 

Ribavirin and Interferon, which are mentioned as COVID-19 drugs, have relatively high side effects and are not recommended as primary antiviral drugs.

 

In particular, some patients confirmed that they could be cured by autoimmunity without antiviral medications.

 

The old and severe patients were advised to consider antiviral medications.

 

On the 11th, the Central Clinical TF held its fifth videoconference and said, "COVID-19 antiviral treatment agreement is being drafted and a TF agreement will be reached within a few days".

 

The central clinical TF consists of medical staff and specialists from the national COVID-19 confirmed patient care hospital, centered on the National Medical Center.

 

A total of 10 medical institutions and 20 experts participated in the 5th meeting to find out the diagnosis of patients in each institution, review discharge criteria, antiviral use criteria, systematic collection and research cooperation of clinical information, prevent unnecessary social confusion, and topics include formal briefing regularization issues to provide prompt and accurate information.

 

A prominent part is the recommendation for antiviral administration.

 

The central clinical TF is in consensus on COVID-19 antiviral treatment.

 

Drugs to be considered for primary administration include AIDS treatment Kaletra and malaria treatment Chloroquine and Hydroxychloroquine.

 

Ribavirin and Interferon are also mentioned as treatments, but the side effects are relatively high and TF is not recommended as primary drugs.

 

Regarding the discharge criteria associated with the fourth discharge patient (No.

 

11), the TF said that the standards for release of quarantine were applied in MERS.

 

If the viral gene is not detected twice in a row after 48 hours after clinical improvement of symptoms, it can be released.

 

In fact, 11th confirmed patient who was discharged for the fourth time on the 10th was diagnosed with symptoms of the 6th patient's family.

 

The symptoms improved from the 3rd and discharged after being negatively assessed by viral genetic tests on the 5th and the 7th.

 

The TF said that it will enable the first-time clinicians to treat infectious diseases abroad for the future operation to quickly identify the characteristics of the disease and to create the basis for treating and responding to infectious diseases.

 

Since the 3rd, they have been sharing and discussing patients' treatment experiences through three video conferences every Monday, Wednesday and Friday.

 

It was diagnosed that COVID-19 air transmission could not be determined about the number of patients and the possibility of air infection on the Japanese cruise ship, which is a national concern.

 

Air propagation (droplet infection) is rare, because the density of pathogens is so important that the disease cannot be transmitted to distant people.

 

The emergence of a large number of patients from Japanese cruise ships is a situation where many people are crowded in a confined space, where direct and indirect contact and splash propagation can occur frequently.

 

TF said that there are four infectious diseases that have been clearly identified as airborne, including measles, tuberculosis, smallpox, and chickenpox.

 

"We are working with the KCDC and the MOHW on a variety of topics, including clarifying the role and status of the TF as soon as possible, evaluating patients for possible discharge, developing clinical guidelines, cooperating with the WHO, and making efficient use of medical resources, and in order to accumulate the ability to cope with emerging infectious diseases, and a permanent committee needs to be operated in a developmental form".